Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=80 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Phase 2 N=127 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
Phase 2 N=57 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=65 Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 3 N=903 Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Carcinoma, Renal Cell
Primary: Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population — 542; 461 days — p=0.146
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 2 N=69 CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Clear Cell Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905
Phase 2 N=26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Kidney Cancer
Primary: Progression Free Survival — 9.6 months
Phase 2 N=305 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Percentage of Participants With Disease Progression Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Via Independent Review Committee (IRC)…
Phase 3 N=821 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Primary: Overall Survival (OS) at Primary Endpoint — 25.00; 19.55 months — p=0.0018
Phase 2 N=146 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Renal Cell Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants
Phase 2 N=225 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants
Phase 4 N=29 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Metastatic Renal Cell Carcinoma (mRCC)
Primary: Percentage of Progression-free Patients by Month 6 — 8.3; 46.2 Percentage of participants
N/A N=684 Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Carcinoma · Renal Cell
Primary: Progression Free Survival (PFS) — 8.394; 6.177 Months
Phase 2 N=31 A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Primary: Objective Response Rate (ORR) — 25.8 percentage of participants
Phase 2 N=106 A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants
Phase 2 N=119 High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Renal Cancer · Kidney Cancer
Primary: Progression-free Survival — 6.0; 5.7 months
N/A N=448 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Categorical Best Overall Response — 13; 130; 120; 58 Participants
Phase 3 N=886 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Renal Cell Cancer
Primary: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants — 13.8; 7.2 Months…
Phase 2 N=164 Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants
Phase 2 N=45 SLM + Axitinib for Clear Cell RCC
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Primary: Incidence of Adverse Events (AE) Per CTCAE 4.03 — 3; 5; 7; 20 Participants